# Therapair Product Intellectual Property Agreement

## ðŸ“‹ Document Overview

**Parties:** Prequel Pty Ltd (65%) | Unison Mental Health Pty Ltd (35%)  
**Product:** Therapair Matching Technology and Platform  
**Purpose:** Define joint ownership and commercialization rights  
**Effective Date:** [DATE]  
**Version:** 1.0

---

## 1. DEFINITIONS

### **1.1 Key Terms**
- **"Product"** means the Therapair matching technology, platform, and all related intellectual property
- **"Prequel"** means Prequel Pty Ltd (ACN: [TO BE ASSIGNED])
- **"Unison"** means Unison Mental Health Pty Ltd (ACN: [TO BE ASSIGNED])
- **"Parties"** means Prequel and Unison collectively
- **"IP"** means intellectual property including patents, trademarks, copyrights, trade secrets, and know-how
- **"Product IP"** means all IP related to the Product
- **"Revenue"** means all income generated from the Product

### **1.2 Product Definition**
The Product includes but is not limited to:
- **Matching Algorithm:** AI/ML technology for therapist-client matching
- **User Interface:** Web platform, mobile apps, and user experience
- **Data Models:** Data structures and processing methods
- **Business Processes:** Matching workflows and methodologies
- **Brand Assets:** Trademarks, logos, and brand elements
- **Software Code:** All code, algorithms, and technical implementations

---

## 2. OWNERSHIP STRUCTURE

### **2.1 Joint Ownership**
- **Prequel Ownership:** 65% of all Product IP
- **Unison Ownership:** 35% of all Product IP
- **Joint Ownership:** All Product IP is owned jointly by both parties
- **Proportional Rights:** Rights and obligations are proportional to ownership

### **2.2 IP Categories**
- **Patents:** Jointly owned, filed in both parties' names
- **Trademarks:** Jointly owned, registered in both parties' names
- **Copyrights:** Jointly owned, registered in both parties' names
- **Trade Secrets:** Jointly owned, protected by confidentiality agreements
- **Know-How:** Jointly owned, shared between parties

### **2.3 Background IP**
- **Prequel Background IP:** Retained by Prequel, licensed to Product
- **Unison Background IP:** Retained by Unison, licensed to Product
- **Third-Party IP:** Licensed to Product as needed
- **New IP:** All new IP developed for Product is jointly owned

---

## 3. DEVELOPMENT RIGHTS

### **3.1 Development Authority**
- **Lead Developer:** Prequel has primary responsibility for Product development
- **Clinical Input:** Unison provides clinical expertise and guidance
- **Joint Decisions:** Major development decisions require both parties' input
- **Development Standards:** All development must meet agreed standards

### **3.2 Development Process**
- **Planning:** Joint development planning and roadmap
- **Implementation:** Prequel leads implementation with Unison input
- **Testing:** Joint testing and quality assurance
- **Review:** Regular review and approval of development progress

### **3.3 Development Resources**
- **Prequel Resources:** Technical development, engineering, design
- **Unison Resources:** Clinical expertise, practitioner relationships, industry knowledge
- **Shared Resources:** Joint funding for development activities
- **External Resources:** Third-party contractors as needed

---

## 4. COMMERCIALIZATION RIGHTS

### **4.1 Commercialization Authority**
- **Independent Rights:** Both parties can commercialize Product independently
- **Joint Commercialization:** Both parties can commercialize together
- **Third-Party Licensing:** Both parties can license Product to third parties
- **White-Label Rights:** Both parties can offer white-label solutions

### **4.2 Commercialization Methods**
- **Direct Sales:** Both parties can sell Product directly
- **Licensing:** Both parties can license Product to third parties
- **Partnerships:** Both parties can form partnerships using Product
- **SaaS Services:** Both parties can offer Product as a service

### **4.3 Commercialization Standards**
- **Quality Standards:** All commercialization must meet agreed standards
- **Brand Guidelines:** All commercialization must follow brand guidelines
- **Clinical Standards:** All commercialization must meet clinical standards
- **Legal Compliance:** All commercialization must comply with applicable laws

---

## 5. REVENUE SHARING

### **5.1 Revenue Allocation**
- **Prequel Share:** 65% of all Product Revenue
- **Unison Share:** 35% of all Product Revenue
- **Revenue Types:** All revenue types are shared proportionally
- **Payment Terms:** Revenue sharing within 30 days of receipt

### **5.2 Revenue Categories**
- **Direct Sales Revenue:** 65% Prequel | 35% Unison
- **Licensing Revenue:** 65% Prequel | 35% Unison
- **Partnership Revenue:** 65% Prequel | 35% Unison
- **White-Label Revenue:** 65% Prequel | 35% Unison
- **Future Product Revenue:** 65% Prequel | 35% Unison

### **5.3 Revenue Reporting**
- **Monthly Reports:** Detailed revenue reports within 15 days
- **Annual Reports:** Comprehensive annual revenue reports
- **Audit Rights:** Both parties have right to audit revenue
- **Dispute Resolution:** Revenue disputes resolved through arbitration

---

## 6. INTELLECTUAL PROPERTY PROTECTION

### **6.1 Patent Protection**
- **Filing Strategy:** Joint patent filing in both parties' names
- **Patent Costs:** Shared proportionally (65% Prequel | 35% Unison)
- **Patent Maintenance:** Joint maintenance of patent portfolio
- **Patent Enforcement:** Joint enforcement of patent rights

### **6.2 Trademark Protection**
- **Registration Strategy:** Joint trademark registration
- **Trademark Costs:** Shared proportionally
- **Trademark Maintenance:** Joint maintenance of trademark portfolio
- **Trademark Enforcement:** Joint enforcement of trademark rights

### **6.3 Copyright Protection**
- **Registration Strategy:** Joint copyright registration
- **Copyright Costs:** Shared proportionally
- **Copyright Maintenance:** Joint maintenance of copyright portfolio
- **Copyright Enforcement:** Joint enforcement of copyright rights

### **6.4 Trade Secret Protection**
- **Confidentiality Agreements:** All employees and contractors
- **Access Controls:** Restricted access to trade secrets
- **Security Measures:** Comprehensive security measures
- **Monitoring:** Regular monitoring of trade secret protection

---

## 7. LICENSING RIGHTS

### **7.1 Internal Licensing**
- **Product Use:** Both parties can use Product for their own purposes
- **Modification Rights:** Both parties can modify Product for their use
- **Derivative Works:** Both parties can create derivative works
- **Sublicensing:** Both parties can sublicense Product to affiliates

### **7.2 External Licensing**
- **Third-Party Licensing:** Both parties can license Product to third parties
- **Licensing Terms:** Standard licensing terms to be agreed
- **Revenue Sharing:** Licensing revenue shared proportionally
- **Approval Rights:** Major licensing deals require both parties' approval

### **7.3 Cross-Licensing**
- **Background IP:** Parties can cross-license background IP
- **Product IP:** Parties can cross-license Product IP
- **Mutual Licensing:** Mutual licensing agreements as needed
- **Licensing Fees:** Licensing fees to be negotiated separately

---

## 8. DECISION MAKING

### **8.1 Product Decisions**
- **Development Decisions:** Prequel leads with Unison input
- **Commercialization Decisions:** Both parties can act independently
- **Major Decisions:** 75% approval required for major decisions
- **Clinical Decisions:** Unison has veto power on clinical matters

### **8.2 IP Decisions**
- **Patent Decisions:** Joint decision-making
- **Trademark Decisions:** Joint decision-making
- **Copyright Decisions:** Joint decision-making
- **Trade Secret Decisions:** Joint decision-making

### **8.3 Business Decisions**
- **Strategic Decisions:** Joint decision-making
- **Financial Decisions:** Joint decision-making
- **Partnership Decisions:** Joint decision-making
- **Exit Decisions:** Joint decision-making

---

## 9. CONFIDENTIALITY

### **9.1 Confidential Information**
- **Product Information:** All Product-related information
- **Technical Information:** All technical information
- **Business Information:** All business information
- **Financial Information:** All financial information

### **9.2 Confidentiality Obligations**
- **Non-Disclosure:** Parties cannot disclose confidential information
- **Non-Use:** Parties cannot use confidential information for other purposes
- **Protection:** Parties must protect confidential information
- **Return:** Parties must return confidential information on termination

### **9.3 Exceptions**
- **Public Information:** Information that becomes public
- **Independent Development:** Information developed independently
- **Third-Party Disclosure:** Disclosure to third parties with consent
- **Legal Requirements:** Disclosure required by law

---

## 10. TERMINATION

### **10.1 Termination Events**
- **Mutual Agreement:** Termination by mutual agreement
- **Breach:** Material breach not cured within 30 days
- **Insolvency:** Bankruptcy or insolvency of either party
- **Death/Disability:** Death or permanent disability of key person

### **10.2 Effect of Termination**
- **IP Ownership:** Joint ownership continues
- **Commercialization Rights:** Both parties retain commercialization rights
- **Revenue Sharing:** Revenue sharing continues
- **Confidentiality:** Confidentiality obligations continue

### **10.3 Post-Termination Rights**
- **Product Use:** Both parties can continue using Product
- **Commercialization:** Both parties can continue commercializing
- **Licensing:** Both parties can continue licensing
- **Development:** Both parties can continue developing

---

## 11. DISPUTE RESOLUTION

### **11.1 Dispute Resolution Process**
1. **Direct Negotiation:** 30 days good faith negotiation
2. **Mediation:** 60 days mediation with agreed mediator
3. **Arbitration:** Binding arbitration under Australian Arbitration Act
4. **Litigation:** Court proceedings as last resort

### **11.2 Governing Law**
- **Jurisdiction:** Victoria, Australia
- **Governing Law:** Australian law
- **Courts:** Victorian courts have jurisdiction
- **Language:** English language for all proceedings

---

## 12. GENERAL PROVISIONS

### **12.1 Entire Agreement**
This agreement constitutes the entire agreement between the parties and supersedes all prior negotiations, representations, or agreements.

### **12.2 Amendment**
This agreement may only be amended by written agreement signed by all parties.

### **12.3 Severability**
If any provision is held invalid or unenforceable, the remaining provisions shall remain in full force and effect.

### **12.4 Assignment**
This agreement may not be assigned without written consent of all parties.

### **12.5 Notices**
All notices must be in writing and delivered to the registered office of each party.

---

## 13. SIGNATURES

**Prequel Pty Ltd**  
Signature: _________________________  
Name: [AUTHORIZED REPRESENTATIVE]  
Title: [TITLE]  
Date: _________________________

**Unison Mental Health Pty Ltd**  
Signature: _________________________  
Name: [AUTHORIZED REPRESENTATIVE]  
Title: [TITLE]  
Date: _________________________

---

**Document Version:** 1.0  
**Last Updated:** October 28, 2025  
**Legal Review Required:** Yes  
**Next Review:** November 28, 2025
